Israel Englander Iovance Biotherapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 50,000 shares of IOVA stock, worth $507,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,000

Previous 1,616,861 96.91%

Holding current value

$507,500

Previous $24 Million 98.33%

% of portfolio

0.0%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$7.78 - $14.19 $11.3 Million - $20.6 Million	-1,450,712 Reduced 89.72%	166,149 $1.33 Million
Q1 2024 May 15, 2024	BUY	$7.59 - $17.47 $5.14 Million - $11.8 Million	677,315 Added 72.09%	1,616,861 $24 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $8.72 Million - $23.5 Million	-2,641,122 Reduced 73.76%	939,546 $7.64 Million
Q2 2023 Aug 14, 2023	BUY	$5.36 - $9.06 $900,849 - $1.52 Million	168,069 Added 4.92%	3,580,668 $25.2 Million
Q1 2023 May 15, 2023	BUY	$5.53 - $8.22 $12.3 Million - $18.3 Million	2,229,060 Added 188.34%	3,412,599 $20.9 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $10.0 $210,334 - $374,260	-37,426 Reduced 3.07%	1,183,539 $7.56 Million
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $1.81 Million - $2.49 Million	-190,222 Reduced 13.48%	1,220,965 $11.7 Million
Q2 2022 Aug 15, 2022	SELL	$6.38 - $18.33 $6.13 Million - $17.6 Million	-961,220 Reduced 40.52%	1,411,187 $15.6 Million
Q1 2022 May 16, 2022	BUY	$12.38 - $19.1 $25.3 Million - $39 Million	2,042,116 Added 618.28%	2,372,407 $39.5 Million
Q4 2021 Feb 14, 2022	SELL	$16.55 - $27.63 $4.15 Million - $6.93 Million	-250,686 Reduced 43.15%	330,291 $6.31 Million
Q1 2021 May 17, 2021	BUY	$28.67 - $52.59 $11.6 Million - $21.2 Million	403,549 Added 227.44%	580,977 $18.4 Million
Q4 2020 Feb 16, 2021	SELL	$28.04 - $50.26 $17.8 Million - $31.9 Million	-634,217 Reduced 78.14%	177,428 $8.23 Million
Q3 2020 Nov 16, 2020	BUY	$27.75 - $36.3 $6.22 Million - $8.14 Million	224,136 Added 38.15%	811,645 $26.7 Million
Q2 2020 Aug 14, 2020	BUY	$27.21 - $41.0 $11.7 Million - $17.6 Million	429,579 Added 272.01%	587,509 $16.1 Million
Q1 2020 May 14, 2020	SELL	$19.54 - $38.85 $4.86 Million - $9.66 Million	-248,596 Reduced 61.15%	157,930 $4.73 Million
Q3 2019 Nov 14, 2019	BUY	$17.99 - $26.0 $5.09 Million - $7.36 Million	283,007 Added 229.12%	406,526 $7.4 Million
Q2 2019 Aug 14, 2019	BUY	$9.78 - $24.52 $1.03 Million - $2.58 Million	105,112 Added 571.04%	123,519 $5.53 Million
Q1 2019 May 14, 2019	BUY	$8.41 - $11.26 $154,802 - $207,262	18,407 New	18,407 $175,000
Q4 2018 Feb 14, 2019	SELL	$7.51 - $11.93 $453,506 - $720,416	-60,387 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$11.25 - $17.7 $7.34 Million - $11.5 Million	-652,535 Reduced 91.53%	60,387 $679,000
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $2.52 Million - $3.43 Million	202,558 Added 39.69%	712,922 $9.13 Million
Q1 2018 May 15, 2018	SELL	$8.1 - $19.5 $1.13 Million - $2.72 Million	-139,287 Reduced 21.44%	510,364 $8.63 Million
Q4 2017 Feb 14, 2018	SELL	$6.65 - $9.25 $9.52 Million - $13.2 Million	-1,431,829 Reduced 68.79%	649,651 $5.2 Million
Q3 2017 Nov 14, 2017	BUY	$4.45 - $8.55 $9.26 Million - $17.8 Million	2,081,480	2,081,480 $16.1 Million

Others Institutions Holding IOVA

# of Institutions

323

Shares Held

239M

Call Options Held

1.27M

Put Options Held

1.68M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.6B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account